BMNDF (Biomind Labs) Return-on-Tangible-Asset: -2,971.43% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biomind Labs Return-on-Tangible-Asset?

Biomind Labs BMNDF Return-on-Tangible-Asset is -2,971.43% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Biomind Labs ranks worse than 99.72% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Biomind Labs's annualized Net Income for the quarter that ended in Mar. 2026 was $-0.42 Mil. Biomind Labs's average total tangible assets for the quarter that ended in Mar. 2026 was $0.01 Mil. Therefore, Biomind Labs's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -2,971.43%.

The historical rank and industry rank for Biomind Labs's Return-on-Tangible-Asset or its related term are showing as below:

BMNDF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3096.2   Med: -471.34   Max: -171.35
Current: -3096.2

During the past 5 years, Biomind Labs's highest Return-on-Tangible-Asset was -171.35%. The lowest was -3096.20%. And the median was -471.34%.

BMNDF's Return-on-Tangible-Asset is ranked worse than
99.72% of 1416 companies
in the Biotechnology industry
Industry Median: -35.76 vs BMNDF: -3096.20

Biomind Labs  (OTCPK:BMNDF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Biomind Labs Return-on-Tangible-Asset Related Terms


Biomind Labs Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Biomind Labs's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomind Labs Return-on-Tangible-Asset Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
-171.36 -228.20 -1,462.58 -452.17 -2,073.17

Biomind Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -864.52 -2,228.57 -1,043.04 -3,889.66 -2,971.43

BMNDF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Biomind Labs's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Return-on-Tangible-Asset falls into.



Biomind Labs Return-on-Tangible-Asset Calculation

Biomind Labs's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-0.85/( (0.041+0)/ 1 )
=-0.85/0.041
=-2,073.17 %

Biomind Labs's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-0.416/( (0+0.014)/ 1 )
=-0.416/0.014
=-2,971.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -2,971.43% mean?
Biomind Labs (BMNDF) has a Return-on-Tangible-Asset of -2,971.43% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Biomind Labs and its competitors. According to the industry distribution chart, Biomind Labs ranks #1412 out of 1416 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Biomind Labs' Return-on-Tangible-Asset too high?
Biomind Labs' current Return-on-Tangible-Asset is -2,971.43%. Based on the distribution chart, Biomind Labs ranks #1412 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Biomind Labs' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biomind Labs ranks #1412 out of 1416 companies for Return-on-Tangible-Asset. This places Biomind Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Biomind Labs and its competitors. Biomind Labs's current Return-on-Tangible-Asset is -2,971.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomind Labs stock overvalued right now?
Biomind Labs (BMNDF) has a current Return-on-Tangible-Asset of -2,971.43%. The current Return-on-Tangible-Asset is -2,971.43%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Biomind Labs (BMNDF), the current Return-on-Tangible-Asset is -2,971.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomind Labs Business Description

Other Exchanges BMND:Canada
Address 701 West Georgia Street, Suite 515, Vancouver, BC, CAN, V7Y 1C6
Biomind Labs Inc is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. The firm is developing pharmaceutical solutions and combined formulations of the main natural psychedelic molecules with the objective of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.